Target Feasibility Assessment

Not all targets are equally suitable for a biologics approach - find out before in-vivo testing your candidate

We assess site of expression, expression levels and turnover rates and factor in the PK properties of a biologics to test if meaningful PK/PD properties are obtained. The question we address is, can a meaningful amount of antibody inhibit your target for a sufficient long time to have an acceptable dosing interval in patients. Thus this activity allows you at a very early stage of the project to rank and select targets based on their kinetic properties and to lower the risk of developing a compound with unrealistic dosing requirements.

Further, potential secondary effects mediated by competition with endogenous ligands can be modelled for an early assessment of side effects.